|Mr. Andrew Rackear||CEO & Sec.||161.8k||N/A||1954|
|Mr. Richard L. Feinstein||VP of Fin. & CFO||151.12k||N/A||1943|
Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in licensing drug products. Its marketed drug products include PegIntron and Sylatron. Enzon Pharmaceuticals, Inc.was founded in 1981 and is headquartered in Cranford, New Jersey.
Enzon Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.